BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Glioblastoma response to standard treatment stratifies patients in
 to two responder subtypes\, creating the potential for precision medicine 
 - Dr Lucy Stead\, University of Leeds
DTSTART:20231122T110000Z
DTEND:20231122T120000Z
UID:TALK205780@talks.cam.ac.uk
CONTACT:Kirsty Shepherd
DESCRIPTION:Glioblastoma (GBM) brain tumours lacking IDH1 mutations (IDHwt
 ) have the worst prognosis of all adult brain cancers. Patients receive su
 rgery and chemoradiotherapy but tumours almost always fatally recur. Using
  RNAseq data from 107 pairs of pre- and post-standard treatment locally re
 current IDHwt GBM tumours\, we identified two responder subtypes based on 
 therapy-driven changes in gene expression. In two thirds of patients a spe
 cific subset of genes is up-regulated from primary to recurrence (Up respo
 nders) and in one third the same genes are down-regulated (Down responders
 ). Characterisation of the responder subtypes indicates subtype-specific a
 daptive treatment resistance mechanisms. In Up responders treatment enrich
 es for quiescent proneural GBM stem cells and differentiated neoplastic ce
 lls with increased neurotransmitter signalling\, whereas Down responders c
 ommonly undergo therapy-driven mesenchymal transition. Stratifying GBM tum
 ours by response subtype may lead to more effective treatment. 
LOCATION:West Hub\, West 2
END:VEVENT
END:VCALENDAR